Mithra pharmaceuticals s.a. private company information – bloomberg reasons for hormonal imbalance in females

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics primarily for treating women’s fertility, contraception, and menopause needs in Belgium, the Netherlands, Luxembourg, and internationally. Its two lead development candidates include Estelle, which in a Phase III clinical trial, a fifth generation oral contraceptive in Europe and North America under the E4 Freedom name; and Donesta, which is in a Phase II clinical trial that is used for a new generation of hormone therapy with the oral administration of Estetrol (E4) for vasomotor menopausal symptoms relief. The company’s research and development pipeline consists of three therapeutics, such as Myring, a con…

Mithra Pharmaceuticals S.A. develops, manufactures, and markets complex therapeutics primarily for treating women’s fertility, contraception, and menopause needs in Belgium, the Netherlands, Luxembourg, and internationally.


Its two lead development candidates include Estelle, which in a Phase III clinical trial, a fifth generation oral contraceptive in Europe and North America under the E4 Freedom name; and Donesta, which is in a Phase II clinical trial that is used for a new generation of hormone therapy with the oral administration of Estetrol (E4) for vasomotor menopausal symptoms relief. The company’s research and development pipeline consists of three therapeutics, such as Myring, a contraceptive vaginal ring releasing a combination of hormones; Zoreline, a biodegradable subcutaneous implant for use in prostate and breast cancers, and benign gynecological indications; and Tibelia, a solution for treating menopause and osteoporosis. It provides products in polymeric forms, sterile injectable products, and hormonal tablets. Mithra Pharmaceuticals S.A. was founded in 1999 and is headquartered in Liège, Belgium.

Mithra Pharmaceuticals S.A. announced consolidated earnings results for the year ended December 31, 2017. For the year, the company reported revenues of EUR 46,252,000 against EUR 22,468,000 a year ago. Operating loss was EUR 21,081,000 against EUR 35,976,000 a year ago. Negative financial result was EUR 25,345,000 against EUR 4,627,000 a year ago. Loss before taxes was EUR 46,426,000 against EUR 40,635,000 a year ago. Net loss for the year attributable to the owners of the parent was EUR 35,006,000 against EUR 35,087,000 a year ago. Basic and diluted earnings per share were EUR 1.37 against EUR 1.13 a year ago. Net cash used in operating activities was EUR 34,921,000 against EUR 24,676,000 a year ago. Payment for acquisition of tangible fixed assets was EUR 45,434,000 against EUR 13,795,000 a year ago. Payment for acquisition of intangible fixed assets was EUR 1,255,000 against EUR 2,309,000 a year ago. The main reasons for the increase in Revenues were the Donesta® deal with Japanese market leader Fuji Pharma for which EUR 4 million was recognized, the Estelle® deal with Libbs for EUR 15 million and the commercialization deal with Mayne Pharma for Myring in the US for EUR 10 million. In total, and including additional smaller deals, Mithra recognized EUR 29.4 million in licensing agreements revenue in 2017, compared to EUR 5.5 million in 2016. Additional payments were received related to licensing agreements for which revenue recognition was deferred to future periods. The financial loss for 2017 amounts to EUR 25.3 million and is driven by changes in the fair value of contingent liabilities (earn outs) payables and in the refundable government advances, which are non-cash elements.